$0.86 EPS Expected for BeiGene, Ltd. (BGNE) This Quarter

Wall Street analysts expect BeiGene, Ltd. (NASDAQ:BGNE) to announce earnings per share (EPS) of $0.86 for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for BeiGene’s earnings, with estimates ranging from ($1.10) to $4.72. BeiGene posted earnings of ($1.05) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 181.9%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 28th.

According to Zacks, analysts expect that BeiGene will report full year earnings of ($3.30) per share for the current year, with EPS estimates ranging from ($5.59) to $0.87. For the next fiscal year, analysts expect that the company will post earnings of ($5.06) per share, with EPS estimates ranging from ($5.96) to ($4.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for BeiGene.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the business earned ($1.08) EPS.

Several research analysts recently commented on BGNE shares. Ladenburg Thalmann Financial Services started coverage on shares of BeiGene in a report on Monday, August 7th. They issued a “buy” rating and a $81.00 target price on the stock. Zacks Investment Research downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $86.00 target price (up previously from $43.00) on shares of BeiGene in a report on Tuesday, August 15th. Maxim Group reiterated a “buy” rating and issued a $77.00 target price on shares of BeiGene in a report on Monday, September 11th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $95.00 target price (up previously from $87.00) on shares of BeiGene in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. BeiGene has an average rating of “Buy” and an average price target of $96.67.

TRADEMARK VIOLATION NOTICE: “$0.86 EPS Expected for BeiGene, Ltd. (BGNE) This Quarter” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/16/0-86-eps-expected-for-beigene-ltd-bgne-this-quarter.html.

BeiGene (NASDAQ:BGNE) opened at $80.43 on Thursday. BeiGene has a twelve month low of $26.43 and a twelve month high of $118.95. The company has a quick ratio of 8.38, a current ratio of 8.38 and a debt-to-equity ratio of 0.57.

In related news, CEO John Oyler sold 25,054 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $83.06, for a total value of $2,080,985.24. Following the sale, the chief executive officer now owns 491,891 shares of the company’s stock, valued at $40,856,466.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Amy C. Peterson sold 3,601 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the sale, the chief marketing officer now directly owns 1,201 shares in the company, valued at approximately $99,634.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 179,612 shares of company stock worth $14,531,763. Insiders own 19.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in BeiGene in the second quarter valued at about $111,000. Quantbot Technologies LP bought a new stake in BeiGene in the third quarter valued at about $160,000. Renaissance Technologies LLC bought a new stake in BeiGene in the first quarter valued at about $238,000. Profund Advisors LLC bought a new stake in BeiGene in the second quarter valued at about $248,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in BeiGene in the third quarter valued at about $248,000. 52.09% of the stock is currently owned by institutional investors and hedge funds.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Get a free copy of the Zacks research report on BeiGene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply